Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Incidence of Mucinous Metaplasia in the Prostate of FVB/N Mice (Mus musculus).

Latonen L, Kujala P, Visakorpi T.

Comp Med. 2016;66(4):286-9.

PMID:
27538859
2.

Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.

Noh BJ, Sung JY, Kim YW, Chang SG, Park YK.

Oncol Lett. 2016 Jun;11(6):3621-3630. Epub 2016 Apr 19.

3.

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.

Clin Cancer Res. 2016 Jul 15;22(14):3672-82. doi: 10.1158/1078-0432.CCR-15-2309. Epub 2016 Mar 2.

4.

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.

De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.

Oncotarget. 2016 Mar 29;7(13):15959-76. doi: 10.18632/oncotarget.7557.

5.

Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.

Linn DE, Penney KL, Bronson RT, Mucci LA, Li Z.

Cancer Res. 2016 Apr 1;76(7):1869-81. doi: 10.1158/0008-5472.CAN-15-1911. Epub 2016 Feb 15.

PMID:
26880803
6.

Translating insights of AR signaling from mouse models.

Carver BS.

Transl Androl Urol. 2013 Sep;2(3):197-201. doi: 10.3978/j.issn.2223-4683.2013.09.17. Review.

7.

Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.

Kato M, Banuelos CA, Imamura Y, Leung JK, Caley DP, Wang J, Mawji NR, Sadar MD.

Clin Cancer Res. 2016 Jun 1;22(11):2744-54. doi: 10.1158/1078-0432.CCR-15-2119. Epub 2015 Dec 28.

PMID:
26712685
8.

Concurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate Cancer.

Nodouzi V, Nowroozi M, Hashemi M, Javadi G, Mahdian R.

Int Braz J Urol. 2015 Sep-Oct;41(5):898-905. doi: 10.1590/S1677-5538.IBJU.2014.0036.

9.

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.

Wu C, Jin X, Yang J, Yang Y, He Y, Ding L, Pan Y, Chen S, Jiang J, Huang H.

Oncotarget. 2016 Jan 19;7(3):3440-52. doi: 10.18632/oncotarget.6497.

10.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

PMID:
26615022
11.

Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.

Ojo D, Lin X, Wong N, Gu Y, Tang D.

Cancers (Basel). 2015 Nov 18;7(4):2290-308. doi: 10.3390/cancers7040890. Review.

12.

Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.

Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll PR, Kim W, Ruggero D.

Sci Signal. 2015 Nov 17;8(403):ra116. doi: 10.1126/scisignal.aad5111.

13.

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.

Hu X, Garcia C, Fazli L, Gleave M, Vitek MP, Jansen M, Christensen D, Mulholland DJ.

Sci Rep. 2015 Nov 13;5:15182. doi: 10.1038/srep15182.

14.

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.

Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS, Nelson PS, Yegnasubramanian S, De Marzo AM, Bieberich CJ.

Cancer Res. 2016 Jan 15;76(2):283-92. doi: 10.1158/0008-5472.CAN-14-3280. Epub 2015 Nov 10.

PMID:
26554830
15.

Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5(+)CK8(+) epithelial cells.

Wang Z, Kim J, Teng Y, Ding HF, Zhang J, Hai T, Cowell JK, Yan C.

Oncogene. 2016 Jul 7;35(27):3555-64. doi: 10.1038/onc.2015.417. Epub 2015 Nov 2.

16.

AR-v7 protein expression is regulated by protein kinase and phosphatase.

Li Y, Xie N, Gleave ME, Rennie PS, Dong X.

Oncotarget. 2015 Oct 20;6(32):33743-54. doi: 10.18632/oncotarget.5608.

17.

Stem cells in genetically-engineered mouse models of prostate cancer.

Shibata M, Shen MM.

Endocr Relat Cancer. 2015 Dec;22(6):T199-208. doi: 10.1530/ERC-15-0367. Epub 2015 Sep 4. Review.

18.

Insights into Chemoresistance of Prostate Cancer.

Zhang W, Meng Y, Liu N, Wen XF, Yang T.

Int J Biol Sci. 2015 Aug 1;11(10):1160-70. doi: 10.7150/ijbs.11439. eCollection 2015. Review.

19.

Expression and role of oncogenic miRNA-224 in esophageal squamous cell carcinoma.

He X, Zhang Z, Li M, Li S, Ren L, Zhu H, Xiao B, Shi R.

BMC Cancer. 2015 Aug 6;15:575. doi: 10.1186/s12885-015-1581-6.

20.

Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.

Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ.

PLoS One. 2015 Jul 21;10(7):e0131232. doi: 10.1371/journal.pone.0131232. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0152243. Liu, Xiuqing [corrected to Li, Xiuqing].

Items per page

Supplemental Content

Write to the Help Desk